PBM Act

Summary of Bill: S. 4509 (119th Congress) – Prohibit Common Ownership Between Pharmacy Benefit Managers and Pharmacies

Purpose and intent

• S. 4509 aims to address perceived conflicts of interest and competition concerns by prohibiting common ownership or control between pharmacy benefit managers (PBMs) and pharmacies. The core idea is to reduce potential anti-competitive behavior, favoritism, or steering that could arise when a single entity or closely related entities own both the entity administering drug benefits and the pharmacies that dispense prescription drugs.

Key provisions and changes (highlights)

• Prohibited relationship: The bill would prohibit common ownership or control between any PBM and any pharmacy. This includes ownership stakes or control that would allow one entity to influence both the benefit design/claims processing and the dispensing location.
• Scope of entities: Applies to PBMs and pharmacies operating in the United States, regardless of whether they are affiliated with traditional wholesale/retail distribution models.
• Anticompetitive concerns: The prohibition is intended to reduce potential conflicts of interest where PBMs could steer patients to pharmacies that are under common ownership, potentially affecting drug prices, rebates, network participation, and patient access.
• Enforcement and compliance: The bill would establish mechanisms to enforce the prohibition, including potential penalties or corrective actions for entities that violate the ownership prohibition. (Exact enforcement details, such as penalties, safe harbors, and reporting requirements, would be specified in the bill text.)
• Additional provisions: The legislation may include definitions (e.g., what constitutes “pharmacy benefit manager,” “pharmacy,” “common ownership,” and “control”), effective dates, and transitional arrangements to allow affected entities to separate ownership or reorganize.

Who would be affected

• Pharmacy Benefit Managers (PBMs): PBMs would be restricted from maintaining common ownership with pharmacies.
• Pharmacies: Pharmacies that are owned or controlled by entities also owning PBMs could be required to divest or restructure to comply.
• Consumers/payers: Federal health programs, private insurers, and patients could experience changes in network design, payment, and access dynamics if PBM-pharmacy ownership links are divested, potentially altering pricing transparency and drug access.
• Market participants: Pharmacy chains, independent pharmacies, wholesalers, and PBM affiliates would need to assess ownership structures for compliance.

Procedural and timeline aspects

• Introduction and referral: The bill was introduced in the Senate and referred to the Committee on the Judiciary on May 13, 2026.
• Sponsorship: Lead sponsors include notable figures, with co-sponsors Roger Marshall, Josh Hawley, and Elizabeth Warren, indicating a cross-ideological interest in addressing PBM/pharmacy ownership concerns.
• Status: As of the latest action, it has progressed to committee for hearings and potential markups. No enactment date is specified; typical federal legislation would proceed through committee consideration, potential floor votes, and conference, depending on legislative priorities and chamber alignment.

Potential implications

• Competition and pricing: By separating ownership, the bill could enhance competition among pharmacies and PBMs, potentially affecting rebates, formulary design, and dispensing fees.
• Patient access and transparency: Divestiture of common ownership could improve transparency in network participation and reduce potential conflicts of interest in beneficiary drug access decisions.
• Compliance burden: Entities would incur costs to restructure ownership, divest assets, or create compliant corporate governance arrangements.

Note: The summary reflects the bill’s stated objectives and typical features associated with ownership prohibition proposals. For precise definitions, exact enforcement mechanisms, safe harbors, penalties, and effective dates, consult the full bill text and any committee reports or amendments.